Skip to main content
0

Cart

Dejan Matlak PostManager
Dejan is an anthropologist with experience in academic writing and social science research. During his bachelor studies, he was a teaching assistant at the Research Centre of Petnica. Currently, he is listening to an MA program for Psychology, and he plans to do research and psychotherapy in the future.
follow me
×
Dejan Matlak PostManager
Dejan is an anthropologist with experience in academic writing and social science research. During his bachelor studies, he was a teaching assistant at the Research Centre of Petnica. Currently, he is listening to an MA program for Psychology, and he plans to do research and psychotherapy in the future.
follow me
Latest Posts
  • Monkey Embryos
  • Traditional medicine
  • Plastic Surgery

Vaccination against SARS-CoV-19 is one of the main issues in discussion since the onset of the pandemic. Thankfully, Pfizer/BioNTech and Moderna vaccines are now ready to help humanity deal with the global health crisis. However, the question of who gets the vaccine and in what dose remains active.

Since this is a pandemic the virus is infecting people on all continents. Because of this, the number of people that need vaccination is unprecedented in human history. Furthermore, the vaccines are made in a few countries and then they need to be distributed throughout the globe. Finally, in the clinical trial for the Pfizer/BioNTech and Moderna vaccines the participants received two vaccines.

In short, three issues make the vaccination against SARS-CoV-19 difficult.

  1. The number of people that need the vaccine globally.
  2. The logistics of redistribution of the vaccines in a climate when all countries want to get as much as possible.
  3. To reach 95% immunity against SARS-CoV-19 people need two doses of the vaccine.

The best solution is to vaccinate the majority of the global population with two doses of the new vaccine. However, elementary mathematics reveals that this would require around 10 billion doses. Not only that, but they will have to be produced in a short period to reach maximum effect. Because of this, medical experts are questioning if the two-dose strategy is the best option.

Potential Solution: One-Dose Vaccination

According to the clinical trial and the FDA-approved protocol for vaccination against SARS-CoV-19, two doses are necessary to gain 95% immunity. However, three groups of scientists came out in separate articles claiming that one dose may be a better option.

For more details explore the original articles listed below:

Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment

A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose

Alternative Dose Allocation Strategies to Increase Benefits from Constrained COVID-19 Vaccine Supply

All three articles argue the same even though their points of inquiry differ. That is, because of the above-mentioned reasons it will be hard to satisfy the global demand for two-phase vaccination. Therefore, the idea is that a “one-dose strategy” will ensure that most people get a shot. The alternative to this is to target groups of people with two doses and give no vaccines to everybody else. This will give immunity to certain people but it will not stop the pandemic.

The one-dose approach is not a risky compromise since there are examples of this strategy yielding positive results. One example is the 2016 outbreak of yellow fever in the Democratic Republic of the Congo. At the time, the global supply for yellow fever vaccines was not enough for the vaccination of millions. To maximize the number of vaccinated individuals DR of the Congo developed fractional-dosing strategies. Furthermore, after the yellow fever epidemic, results from fractional-dosing trials demonstrate protective and durable vaccine results.

The Benefits of Single-Dose Vaccination

According to Ruanne V. Barnabas (MBChB, MSc, DPhil) and Anna Wald (MD, MPH), there are four benefits of the single-dose approach.

  • A single-dose approach deals with the global shortage of vaccines.
  • Giving effective protection to as many people as possible is the most ethical approach to vaccination against SARS-CoV-19. Choosing to select specific groups of people or just the segment of the population that can afford the vaccine causes ethical issues.
  • Using a single-dose approach may mitigate the adverse effects of vaccination. As the current trials suggest, people have more severe and long-lasting reactions to the vaccine after the second dose.
  • There are concerns that people will stop implementing social distancing protective measures after two-dose vaccination. Medical experience teaches us that people think that vaccination is the end of an epidemic or pandemic. However, this is not true and people should not stop following the existing rules of hygiene and social interactions immediately after vaccination. The idea is that single-dose vaccination will ensure that people follow the protocol longer.

The exact strategy will be different in every country. However, the one-dose approach is viable and in line with existing health guidelines.

Main Takeaways

  • The global demand for vaccines against SARS-CoV-19 will make it difficult for the majority of the population to get two-doses.
  • Researchers and medical experts claim that a single-dose approach will be more effective in the current scenario.
Close Menu
Conduct Science

Free shipping in local orders over $500

X